贝伐单抗用于肝癌恶性腹水患者的作用及安全性  

Efficacy and safety of bevacizumab in patients with malignant ascites due to liver cancer

作　　者：陈杰 国仁秀 许晨辉[1] 查云萍 CttEN Jie, GUO Ren-xiu, XU Chen-hui, ZHA Yun-ping(Department of Gastroenterology, Beijing Cancer Hospital, Beijing 100142, Chin)

机构地区：[1]北京肿瘤医院消化内科,北京100142

出　　处：《中国肿瘤临床与康复》2018年第3期309-311,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨贝伐单抗用于肝癌恶性腹水患者的作用及安全性。方法选取2013年2月至2017年4月间北京肿瘤医院收治的64例肝癌恶性腹水患者,采用随机数表法分为观察组和对照组,每组32例。观察组患者在顺铂腹腔灌注和引流治疗基础上采用贝伐单抗腹腔灌注治疗,对照组患者采用顺铂腹腔灌注和引流治疗,比较两组患者临床疗效、KPS评分及不良反应情况。结果观察组患者总有效率为84.4%,高于对照组患者的56.3%,差异有统计学意义(P<0.05)。治疗后,观察组患者KPS评分改善有效率为87.5%,高于对照组患者的62.5%,差异有统计学意义(P<0.05)。两组患者不良反应均主要为粒细胞降低、恶心呕吐、贫血和发热等,两组患者不良反应发生率及程度比较,差异无统计学意义(P>0.05)。结论贝伐单抗治疗肝癌恶性腹水患者,疗效确切,安全性较好,值得临床推广应用。Objective To investigate the efficacy and safety of bevacizumab in patients with malignant ascites complicated with liver cancer. Methods Sixty-four patients with malignant ascites due to liver cancer were selected at Beijing Cancer Hospital from February 2013 to April 2017. Patients were randomly divided into an observation group and a control group with 32 patients in each group.The observation group was given cisplatin intraperitoneal perfusion and drainage combined with bevacizumab intraperitoneal perfusion and the control group only received cisplatin intraperitoneal perfusion and drainage. Efficacy,KPS score and adverse reactions were compared between the two groups.Results The overall efficacy rate was 84. 4 % in the observation group which was higher than 56. 3 %of the control group（P〈0. 05）. The improvement in KPS score was 87. 5 % for the the observation group which was higher than 62. 5 % of the control group（P〈0. 05）. Adverse reactions mainly included granulocyte degeneration,nausea and vomiting,anemia and fever,etc. There was no significant difference in the incidence and degree of adverse reactions（P〉0. 05）. Conclusion Bevacizumab is effective and safe in the treatment of malignant ascites due to hepatocellular carcinoma and it is worthy to be popularized and applied in the clinical practice.

关 键 词：肝肿瘤 恶性腹水 贝伐单抗 顺铂 

分 类 号：R735.7[医药卫生—肿瘤]